144 related articles for article (PubMed ID: 32033748)
1. Ubiquitin-specific protease 14 regulates ovarian cancer cisplatin-resistance by stabilizing BCL6 oncoprotein.
Shen J; Hong L; Chen L
Biochem Biophys Res Commun; 2020 Apr; 524(3):683-688. PubMed ID: 32033748
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ubiquitin‑specific protease 14 promotes connexin 32 internalization and counteracts cisplatin cytotoxicity in human ovarian cancer cells.
Luo H; Wang X; Ge H; Zheng N; Peng F; Fu Y; Tao L; Wang Q
Oncol Rep; 2019 Sep; 42(3):1237-1247. PubMed ID: 31322234
[TBL] [Abstract][Full Text] [Related]
3. USP14 as a novel prognostic marker promotes cisplatin resistance via Akt/ERK signaling pathways in gastric cancer.
Fu Y; Ma G; Liu G; Li B; Li H; Hao X; Liu L
Cancer Med; 2018 Nov; 7(11):5577-5588. PubMed ID: 30296012
[TBL] [Abstract][Full Text] [Related]
4. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract][Full Text] [Related]
5. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
6. Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor.
Liao Y; Liu N; Hua X; Cai J; Xia X; Wang X; Huang H; Liu J
Cell Death Dis; 2017 Feb; 8(2):e2585. PubMed ID: 28151478
[TBL] [Abstract][Full Text] [Related]
7. NCK1-AS1 promotes NCK1 expression to facilitate tumorigenesis and chemo-resistance in ovarian cancer.
Chang H; Li B; Zhang X; Meng X
Biochem Biophys Res Commun; 2020 Feb; 522(2):292-299. PubMed ID: 31761329
[TBL] [Abstract][Full Text] [Related]
8. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
9. USP14 Inhibition Regulates Tumorigenesis by Inducing Autophagy in Lung Cancer In Vitro.
Han KH; Kwak M; Lee TH; Park MS; Jeong IH; Kim MJ; Jin JO; Lee PC
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31653087
[TBL] [Abstract][Full Text] [Related]
10. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
[TBL] [Abstract][Full Text] [Related]
11. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
Qin L; Qiu H; Zhang M; Zhang F; Yang H; Yang L; Jia L; Qin K; Jia L; Dou X; Cheng L; Sang M; Zhang C; Shan B; Zhang Z
Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies.
Didier R; Mallavialle A; Ben Jouira R; Domdom MA; Tichet M; Auberger P; Luciano F; Ohanna M; Tartare-Deckert S; Deckert M
Mol Cancer Ther; 2018 Jul; 17(7):1416-1429. PubMed ID: 29703842
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin-specific protease 14 (USP14) regulates cellular proliferation and apoptosis in epithelial ovarian cancer.
Wang Y; Wang J; Zhong J; Deng Y; Xi Q; He S; Yang S; Jiang L; Huang M; Tang C; Liu R
Med Oncol; 2015 Jan; 32(1):379. PubMed ID: 25429837
[TBL] [Abstract][Full Text] [Related]
14. [Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer].
Qi C; Zhang QH; Li JX
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jun; 32(6):817-21. PubMed ID: 22978111
[TBL] [Abstract][Full Text] [Related]
15. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
Niu Q; Liu Z; Gao J; Wang Q
Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
Zhang C; Wang M; Shi C; Shi F; Pei C
Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
[TBL] [Abstract][Full Text] [Related]
17. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
18. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of ubiquitin-specific protease 14 in oncogenesis and development of tumor: Therapeutic implication.
Liu B; Chen J; Zhang S
Life Sci; 2019 Dec; 239():116875. PubMed ID: 31676235
[TBL] [Abstract][Full Text] [Related]
20. Nrf2 induced cisplatin resistance in ovarian cancer by promoting CD99 expression.
Wu J; Zhang L; Li H; Wu S; Liu Z
Biochem Biophys Res Commun; 2019 Oct; 518(4):698-705. PubMed ID: 31472965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
